Enhancing the Pharmaceutical Performance of Herbal Drugs Through Cocrystal Engineering

Solid crystals are single-phase crystals. materials that are not solvates, hydrates, or simple salts and are made up of two or more distinct molecular and ionic compounds, usually in a stoichiometric ratio. API cannot be correctly formulated due to a variety of stability issues; as a result, they are transformed into solid forms like polymorphs, salts, solvates, hydrates, amorphous, and co-crystals. Etter was the first to report the term "co-crystal" and the design guidelines for hydrogen bonding in organic co-crystals. Co-crystallization is thought to be a better option for optimizing therapeutic characteristics since it modifies the molecular interactions and composition of pharmaceutical materials. Solvates, hydrates, co-crystals, and salts are examples of multicomponent crystals that are crucial in the creation of novel solids, especially in the pharmaceutical industry. Drug-drug co-crystals are distinct, solid, single-entity forms and as Drug-Drug co-crystals are distinct from open combinations or FDCs since they are solid, single-entity forms. A cocrystal may be referred to as DDC as both of its constituent parts are APIs. In order to improve curcumin's solubility, stability, and complementing biological activity, the current study attempts to create a unique curcumin-ascorbic acid cocrystal. The development of cocrystal, eutectic, and binary mixtures with an excess of coformer was confirmed by the DSC and XRD data of the solvent-evaporated curcumin-ascorbic acid mixture.